FEN1 drives small cell neuroendocrine carcinoma of the cervix progression and holds promise as a therapeutic target

Small cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare and clinically aggressive subtype of cervical cancer associated with a poor prognosis. To investigate its underlying pathological mechanisms and identify potential therapeutic targets, researchers have increasingly employed single-omics or multi-omics integrated analysis, including single-cell transcriptome sequencing, proteomics, whole-exome sequencing, and genomics. In a study by Jianbing Liu et al., proteomic profiling of SCNECC tumor tissues and adjacent non-tumor tissues revealed that FEN1 drives disease progression by modulating PCNA expression. FEN1 shows promise as a novel therapeutic target for SCNECC. This commentary emphasizes that omics technology is an effective research approach for investigating the pathological mechanisms of SCNECC, and FEN1 shows potential as a novel therapeutic target for SCNECC. However, further experiments are required to elucidate its mechanisms of action.